Molecular genetic abnormalities in the pathogenesis of human lung cancer

Pathology and Oncology Research

Volumn 7, Issue 1, 2001, Pages 6-13

  Forgacs, Eva ^a   Zöchbauer Müller, Sabine ^a   Oláh, Edit ^b   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Angiogenesis; Autocrine; Cell cycle; Methylation; Mutation; Oncogene; Preneoplasia; Signal transduction; Telomerase; Tumor suppressor gene

Indexed keywords

BOMBESIN; GASTRIN RELEASING PEPTIDE; MICROSATELLITE DNA; ONCOPROTEIN; SCATTER FACTOR; TELOMERASE;

ANGIOGENESIS; AUTOCRINE EFFECT; CELL CYCLE; DNA METHYLATION; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR GENETICS; ONCOGENE; PARACRINE SIGNALING; PRECANCER; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHROMOSOME ABERRATIONS; DISEASE SUSCEPTIBILITY; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; LUNG NEOPLASMS; METHYLATION; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; ONCOGENES; PROMOTER REGIONS (GENETICS); STEM CELLS; TOBACCO SMOKE POLLUTION;

EID: 0034950354     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032598     Document Type: Review

References (96)

1. Tobacco smoke carcinogens and lung cancer
2. Molecular damage in the bronchial epithelium of current and former smokers
3. Clonal genetic alterations in the lungs of current and former smokers
4. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
5. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
6. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering
7. Progress in understanding the molecular pathogenesis of human lung cancer
8. A hereditary genetic marker closely associated with microsatellite instability in lung cancer
9. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors
10. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage
11. Telomerase activity in small-cell and non-small-cell lung cancers
12. Bombesin receptor structure and expression in human lung carcinoma cell lines
13. The biology of lung cancer
14. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
15. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095
16. Sex-specific expression of gastrin-releasing peptide receptor: Relationship to smoking history and risk of lung cancer
17. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas
18. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
19. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
20. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung
21. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines
22. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells
23. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- Selective tyrosine kinase inhibitor
24. Lung cancer highlights
25. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas
26. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas
27. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer
28. Insulin-like growth factor expression in human cancer cell lines
29. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products
30. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
31. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer
32. Prognostic impact of mutated K-ras gene in surgically resected non- small cell lung cancer patients
33. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer
34. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer
35. Expression of bcl-2 - Protein in small cell lung cancer
36. bcl-2 protein in non-small-cell lung carcinoma
37. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer
38. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer
39. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23)
40. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer
41. Three distinct regions involved in 3p deletion in human lung cancer
42. Homozygous deletions of human chromosome 3p in lung tumors
43. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: Progress toward the isolation of a lung cancer TSG
44. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations
45. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes
46. Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2)
47. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns
48. Semaphorins as mediators of neuronal apoptosis
49. Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression
50. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
51. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
52. Mutation of a mutL homolog in hereditary colon cancer
53. The DUTT1 gene, a novel NCAM family member is expressed in developing murine neural tissues and has an unusually broad pattern of expression
54. The FHIT gene 3p14.2 is abnormal in lung cancer
55. Loss of Fhit expression in non-small-cell lung cancer: Correlation with molecular genetic abnormalities and clinicopathological features
56. Replacement of Fhit in cancer cells suppresses tumorigenicity
57. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression
58. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines
59. Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours
60. Aberrant promoter methylation of multiple genes in non-small cell lung cancers
61. Promoter methylation and silencing of the retinoic acid receptor-B gene in lung carcinomas
62. Retinoblastoma and subband deletion of chromosome 13
63. The cell cycle and the retinoblastoma protein family
64. Inactivation of the retinoblastoma susceptibility gene in non-small- cell lung cancer
65. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications
66. Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis
67. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma
68. Rb and p16INK4a expression in resected non-small cell lung tumors
69. RB protein status and clinical correlation from 171 cell tines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma
70. Non-ocular cancer in relatives of retinoblastoma patients
71. Role of the INK4a locus in tumor suppression and cell mortality
72. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
73. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers
74. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas
75. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines
76. Mutations and altered expression of p16INK4 in human cancer
77. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
78. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma
79. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer
80. Clinical implications of the p53 gene
81. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
82. p53: A frequent target for genetic abnormalities in lung cancer
83. Molecular epidemiology of human cancer risk: Gene-environment interactions and p53 mutation spectrum in human lung cancer
84. p53 protein accumulates frequently in early bronchial neoplasia
85. Non-small cell lung cancer: Clinical value of new biological predictors
86. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
87. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
88. Mutation analysis of the PTEN/MMAC1 gene in lung cancer
89. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer
90. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
91. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
92. Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma
93. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
94. The molecular epidemiology of lung cancer
95. Genetic susceptibility to tobacco carcinogenesis
96. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer